Notizie e Video - NICOX

Press Release Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma Trial Results expected in May 2025 Last patient in the U.S. in the ongoing NCX 470 Denali Phase 3 trial has also completed their last visit and results remain on track for Q3 2025 March 19, 2025 – release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that the last patient completed their...

Press Release Nicox Extends Cash Runway into Q4 2025 Flexible equity financing line with Vester Finance of up to 10,000,000 shares over 24 months Immediate upfront payment from Vester Finance of €0.5 million extends the cash runway into Q4 2025, enabling focus on future growth Ongoing discussions and business development outreach underway for NCX 470 U.S. partnership Two NCX 470 clinical readouts in 2025 – Whistler Mechanism of Action in Q2 2025 and Denali confirmatory Phase 3 in Q3 2025...

Press Release Nicox Presents New Analysis from the NCX 470 Mont Blanc Trial and Provides Development Update More patients on NCX 470 achieve an intraocular pressure (IOP) of less than or equal to 18 mmHg compared to latanoprost New analysis provides additional data demonstrating differentiation of NCX 470 Development activities on track for U.S. New Drug Application submission targeted in H1 2026 March 3, 2025 – release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Growth Paris:...

Press Release Nicox Announces Scientific Presentation and Conference Attendance in H1 2025 January 28, 2025 – release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced a presentation at the upcoming American Glaucoma Society (AGS) Annual Meeting 2025 and participation in a number of key ophthalmology and financial conferences in the first half of 2025. Presentation of additional analysis of the...

Communiqué de presse Nicox confirme son éligibilité au PEA-PME 22 janvier 2025 – publication à 7H30 Sophia Antipolis, France Nicox SA (Euronext Growth Paris : FR0013018124, ALCOX, éligible PEA-PME), société internationale spécialisée en ophtalmologie, confirme son éligibilité au PEA-PME pour les 12 mois à venir. Pour les besoins de cette confirmation, les critères d'éligibilité des titres de la société Nicox au PEA-PME, prévus par l'article L 221-32-2 du code monétaire et...

Press Release Nicox Provides Business Update and Fourth Quarter 2024 Financial Highlights Last patient recruited in the NCX 470 (bimatoprost grenod) Phase 3 Denali clinical trial with topline results expected in Q3 2025 Fourth quarter 2024 Nicox Group revenue of €13.7 million Cash of €10.7 million as of December 31, 2024, following a €5.2 million debt repayment, which the Company estimates will finance it into the third quarter of 2025 January 21, 2025 – release at 7:30 am CET Sophia...

Communiqué de presse Nicox annonce la première vente commerciale de ZERVIATE en Chine par son partenaire Ocumension, création d’une nouvelle source de revenus récurrents Premier produit commercialisé résultant de la collaboration Nicox-Ocumension Avec ses récentes acquisitions, Ocumension a renforcé sa position d’acteur clé dans le domaine de l’ophtalmologie en Chine Produit disponible à la vente peu après l’approbation grâce à une campagne de fabrication rapide dans...

Press Release Nicox’s Denali Phase 3 Trial of NCX 470 Fully Enrolled in China Earlier than Expected Confirms topline results expected to be reported Q3 2025 NCX 470 demonstrated robust efficacy and safety in topline results from first Phase 3 trial, Mont Blanc NCX 470 partnering efforts will focus on routes for bringing the product to market in the U.S. Results from the NCX 470 Phase 3b Whistler Mechanism of Action trial expected in Q1 2025 December 2, 2024 – release at 7:30 am CET Sophia...

Communiqué de presse Nicox annonce la publication de la partie adaptive de l’étude clinique de phase 3 Mont Blanc sur NCX 470 Une partie adaptative est un outil de design d’étude clinique utile qui a permis d’identifier la dose optimale de NCX 470 dans l’étude Mont Blanc, la première étude de phase 3 de NCX 470 Les deux doses de la solution ophtalmique NCX 470 évaluées, 0,065 % et 0,1 %, ont réduit la pression intraoculaire davantage que le comparateur, latanoprost solution...

Press Release Nicox Provides Third Quarter 2024 update and First Half 2024 Financial Results Topline results from the NCX 470 (bimatoprost grenod) Phase 3 Denali clinical trial expected in Q3 2025 Cash of €19.7 million on September 30, 2024, including the estimated net proceeds of the VYZULTA royalty sale and equity investment announced on October 14, 2024 The Company estimates that it is financed into Q3 2025 October 17, 2024 – release at 7:30 am CET Sophia Antipolis, France Nicox SA...

Press Release Nicox and Soleus Sign $16.5 million Royalty and Equity Financing Gross proceeds of $15 million (€13.7 million) for the sale of Nicox’s net share of the VYZULTA royalty to Soleus Soleus investing $1.5 million (€1.37 million) in Nicox shares, issued at €0.3144 per share, representing a 20% premium to the closing price on October 11, 2024, with attached warrants valued at $0.75 million (€0.69 million) at an exercise price of €0.5240 per share, representing a 100% premium...

Communiqué de presse Nicox et Glaukos signent un accord exclusif de recherche incluant une option de licence mondiale pour NCX 1728 L’option permettra à Glaukos de conclure des accords exclusifs de licence mondiale selon des conditions préalablement convenues, notamment des paiements initiaux et d’étape ainsi que des redevances. Glaukos financera et mènera des activités de recherche préclinique sur NCX 1728 l’évaluant dans le glaucome (y compris la neuroprotection) et dans...

Press Release Nicox Announces Approval of ZERVIATE in China Nicox’s partner, Ocumension Therapeutics, has received approval for ZERVIATE ® for ocular itching in China ZERVIATE ® launch in China will add a further royalty revenue stream for Nicox September 18, 2024 – release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that its exclusive Chinese partner, Ocumension Therapeutics, has...

Press Release Nicox Appoints Christine Placet to Board of Directors; Michele Garufi steps down from Board Christine Placet is CFO of Theranexus, and was formerly CEO of Horama and Trophos Michele Garufi, former Chairman and CEO of Nicox, hands over his Board position after over more than 25 years at the company he co-founded The Nicox Board has now been entirely renewed to bring in the expertise to support the Company’s strategic direction going forward September 4 th , 2024 – release at...

Communiqué de presse Nicox : Recrutement du dernier patient aux Etats-Unis dans l’étude clinique de phase 3 Denali sur NCX 470 Le recrutement se poursuit en Chine, avec les premiers résultats toujours attendus pour le deuxième semestre 2025 NCX 470 a démontré une efficacité robuste et une bonne tolérabilité dans les résultats principaux de la première étude de Phase 3, Mont Blanc 25 juillet 2024 – publication à 7H30 Sophia Antipolis, France Nicox SA (Euronext Growth Paris :...

Press Release Nicox announces attendance at upcoming conferences July 19 th , 2024 – release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced its attendance at several upcoming international conferences: H.C. Wainwright 4th Annual Ophthalmology Virtual Conference, August 15, 2024 (Virtual) H.C. Wainwright 26th Annual Global Investment Conference, September 9-11, 2024 (New York) Investor...

Press Release Nicox Provides Second Quarter 2024 Update Nicox Group revenue of €1.6 million (net revenue 1 €1.0 million) for second quarter 2024 Nicox Group cash of €7.8 million on 30 June 2024 which finances the Company until at least February 2025 July 18 th , 2024 – release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today provided the revenue and cash position for Nicox SA and its subsidiaries...

Press Release Nicox appoints experienced biotech leader Damian Marron as Chair of the Board and Marc Le Bozec as Director Damian Marron is an experienced healthcare executive, non-executive Director/Chair and advisor Marc Le Bozec is an experienced life sciences entrepreneur with a background in finance, organization and strategic consulting Jean-François Labbe retires as Chair and member of the Board at the completion of his term; Les Kaplan has also decided to step down from the Board July 16...

Press Release Nicox: 2024 Ordinary Shareholder Meeting June 27, 2024 – release at 17:30 CET Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, ALCOX), an international ophthalmology company, informs its shareholders that the Ordinary general meeting convened on first call on Friday June 28, 2024, will not be held as the quorum required by law has not been reached. The shareholders of Nicox are thus convened on second call for an Ordinary general meeting on the same resolutions...

Communiqué de presse Nicox annonce le succès de son augmentation de capital avec maintien du droit préférentiel de souscription sous forme d’ABSA d’un montant total de 3,3 millions d’euros et étend son horizon de trésorerie pour poursuivre le développement de NCX 470 Produit brut de l’augmentation de capital, prime d’émission incluse, de 3,3 millions d’euros par émission de 13 154 900 ABSA au prix unitaire de 0,25 euro Nouvel horizon de trésorerie estimé à fin février...